Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax. Issue 2 (28th January 2022)

• Record Type: Journal Article
• Authors: Maravalle, Denise; Filosa, Alessandra; Bigazzi, Catia; Collina, Guido; Galieni, Piero
• Is Part Of: EJHaem. Volume 3:Issue 2(2022)
• Page Start: 517
• Page End: 520
• Publication Date: 2022-01-28
• Subjects: AML -- cyclic therapy -- decitabine -- leukaemia cutis -- long‐term remission -- venetoclax; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.388
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: In February 2020, a 74‐year‐old female was diagnosed with myelomonocytic acute myeloid leukaemia with FLT3 mutation and blasts positive for CD33, BCL‐2 and CD68/PGM1. Not responding to a standard Cytarabine–containing regimen plus Midostaurin, the patient achieved a complete remission (CR) of the disease in the bone marrow following a reinduction therapy with high‐dose Cytarabine but simultaneously relapsed developing leukaemia cutis with disseminated lesions in 80% of the body surface area. After receiving 10 cycles of Decitabine plus Venetoclax the patient achieved and maintains a continuous CR.